Expert consensus on precision surgery for gastric cancer conversion therapy （2025 edition）

doi:10.3877/cma.j.issn.1674-0793.2025.03.001

Abstract

Abstract:

Gastric cancer ranks among the most prevalent and lethal malignancies in China， with approximately 30%-40% of patients diagnosed at stage.Although systemic therapy has modestly improved survival in some cases， the overall prognosis remains poor.In recent years， advancements in precision surgical concepts and oncology research have introduced novel individualized treatment strategies centered on immunotherapy， precision molecular subtyping， and multi-omics testing， offering new opportunities for managing stage gastric cancer.However， there is currently no established consensus in China on the standardized implementation of conversion therapy for stage disease.To address this gap， the Chinese Expert Consensus on Precision Surgery for Gastric Cancer Conversion Therapy （2025 Edition） is developed through multidisciplinary collaboration among experts in gastrointestinal surgery， medical oncology，radiology， and pathology.This consensus systematically reviews the latest clinical evidence on conversion therapy， incorporates insights into critical challenges in Chinese clinical practice， and refines key aspects including patient stratification， molecular guided precision therapy， prediction of conversion success， surgical planning， and perioperative management.The document aims to standardize clinical practices for stage gastric cancer conversion therapy and provide clinicians with scientifically robust and practical decisionmaking guidance.

Key words: Stomach neoplasms, Surgical treatment, Precision, Conversion therapy, Expert consensus

& Endoscopic Surgery Group, Branch of Surgery, Chinese Medical Association Laparoscopic, Cancer Professional Committee, China Anti-Cancer Association Gastric, and Robotic Surgical Society, China Anti-Cancer Association Endoscopic, Board of the Chinese Journal of Digestive Surgery Editorial. Expert consensus on precision surgery for gastric cancer conversion therapy （2025 edition）[J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 145-156.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2025.03.001

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2025/V19/I03/145

References 65

［1］	Jin G， Lv J， Yang M， et al.Genetic risk， incident gastric cancer，and healthy lifestyle： A meta-analysis of genome-wide association studies and prospective cohort study［J］.Lancet Oncol， 2020， 21（10）：1378-1386.
［2］	李国新，赵丽瑛，梁华元.晚期胃癌转化治疗的现状与临床问题［J］.中华消化外科杂志， 2024， 23（1）： 70-74.
［3］	Yoshida K， Yamaguchi K， Okumura N， et al.Is conversion therapy possible in stage Ⅳ gastric cancer： the proposal of new biological categories of classification［J］.Gastric Cancer， 2016， 19（2）： 329-338.
［4］	Li S， Yu W， Xie F， et al.Neoadjuvant therapy with immune checkpoint blockade， antiangiogenesis， and chemotherapy for locally advanced gastric cancer［J］.Nat Commun， 2023， 14（1）： 8.
［5］	Yasufuku I， Tsuchiya H， Fujibayashi S， et al.Oligometastasis of gastric cancer： A review［J］.Cancers （Basel）， 2024， 16（3）： 673.
［6］	Fujitani K， Yang HK， Mizusawa J， et al.Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor （REGATTA）： A phase 3，randomised controlled trial［J］.Lancet Oncol， 2016， 17（3）： 309-318.
［7］	Yoshida K， Yasufuku I， Terashima M， et al.International retrospective cohort study of conversion therapy for stage Ⅳ gastric cancer 1 （CONVO-GC-1）［J］.Ann Gastroenterol Surg， 2022， 6（2）：227-240.
［8］	Manji GA， Lee S， Del Portillo A， et al.Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma［J］.JAMA Oncol， 2023， 9（12）： 1702-1707.
［9］	Hodan R， Gupta S， Weiss JM， et al.Genetic/familial highrisk assessment： colorectal， endometrial， and gastric， version 3.2024，NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw， 2024， 22（10）： 695-711.
［10］	Guo W， Ou G， Li X， et al.Screening of the nutritional risk of patients with gastric carcinoma before operation by NRS 2002 and its relationship with postoperative results［J］.J Gastroenterol Hepatol， 2010， 25（4）： 800-803.
［11］	Cho JW， Youn J， Kim EM， et al.Associations of patient-generated subjective global assessment （PG-SGA） and NUTRISCORE with survival in gastric cancer patients： timing matters， a retrospective cohort study［J］.BMC Gastroenterol， 2022， 22（1）： 468.
［12］	中华医学会外科学分会腹腔镜与内镜外科学组，中国医师协会外科医师分会上消化道外科医师专家工作组，《中华消化外科杂志》编辑委员会.精准胃癌外科诊疗中国专家共识（2024版）［J］.中华消化外科杂志， 2024， 23（3）： 323-333.
［13］	Zhang LY， Ma JJ， Zang L， et al.Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction［J］.J Surg Oncol， 2021， 123（Suppl 1）： S8-S14.
［14］	Ignjatovic N， Stojanov D， Djordjevic M， et al.Perforation of gastric cancer-what should the surgeon do？［J］.Bosn J Basic Med Sci，2016， 16（3）： 222-226.
［15］	Pan Z， Zhang H， Yan C， et al.Determining gastric cancer resectability by dynamic MDCT［J］.Eur Radiol， 2010， 20（3）： 613-620.
［16］	Hwang SW， Lee DH， Lee SH， et al.Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector- row computed tomography［J］.J Gastroenterol Hepatol， 2010， 25（3）：512-518.
［17］	Kim YN， Choi D， Kim SH， et al.Gastric cancer staging at isotropic MDCT including coronal and sagittal MPR images： endoscopically diagnosed early vs.advanced gastric cancer［J］.Abdom Imaging，2009， 34（1）： 26-34.
［18］	Yan C， Zhu ZG， Yan M， et al.Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma： A large-scale Chinese study［J］.J Surg Oncol，2009， 100（3）： 205-214.
［19］	Chen CY， Hsu JS， Wu DC， et al.Gastric cancer： preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results［J］.Radiology， 2007， 242（2）： 472-482.
［20］	Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2021 （6th edition）［J］.Gastric Cancer， 2023，26（1）： 1-25.
［21］	Eisenhauer EA， Therasse P， Bogaerts J， et al.New response evaluation criteria in solid tumours： revised RECIST guideline（version 1.1）［J］.Eur J Cancer， 2009， 45（2）： 228-247.
［22］	Takahashi S， Hirayama M， Kuroiwa G， et al.Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer： evaluating the response to chemotherapy， a retrospective analysis［J］.Gastric Cancer， 2013， 16（4）： 543-548.
［23］	Seymour L， Bogaerts J， Perrone A， et al.iRECIST： guidelines for response criteria for use in trials testing immunotherapeutics［J］.Lancet Oncol， 2017， 18（3）： e143-e152.
［24］	Kim YK， Lee MW， Lee WJ， et al.Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis （ 1.5 cm in diameter）［J］.Invest Radiol， 2012，47（3）： 159-166.
［25］	Bosch KD， Chicklore S， Cook GJ， et al.Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment［J］.Eur J Nucl Med Mol Imaging，2020， 47（4）： 759-767.
［26］	Kim HW， Won KS， Song BI， et al.Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer［J］.Nucl Med Mol Imaging， 2015， 49（2）： 135-142.
［27］	Ho S， Tay KV.Systematic review of diagnostic tools for peritoneal metastasis in gastric cancer-staging laparoscopy and its alternatives［J］.World J Gastrointest Surg， 2023， 15（10）： 2280-2293.
［28］	Ruan D， Zhao L， Cai J， et al.Evaluation of FAPI PET imaging in gastric cancer： A systematic review and meta-analysis［J］.Theranostics， 2023， 13（13）： 4694-4710.
［29］	Qin C， Shao F， Gai Y， et al.（68）Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas： comparison with ¹⁸F-FDG PET/CT［J］.J Nucl Med， 2022， 63（1）： 81-88.
［30］	中国抗癌协会胃癌专业委员会.胃癌腹膜转移诊治中国专家共识（2023 版）［J］.中华胃肠外科杂志， 2023， 26（8）： 717-728.
［31］	Kim SW.The result of conversion surgery in gastric cancer patients with peritoneal seeding［J］.J Gastric Cancer， 2014， 14（4）： 266-270.
［32］	Irino T， Sano T， Hiki N， et al.Diagnostic staging laparoscopy in gastric cancer： A prospective cohort at a cancer institute in Japan［J］.Surg Endosc， 2018， 32（1）： 268-275.
［33］	Huang J， Luo H， Zhou C， et al.Yield of staging laparoscopy for incurable factors in Chinese patients with advanced gastric cancer［J］.J Laparoendosc Adv Surg Tech A， 2018， 28（1）： 19-24.
［34］	Kodera Y， Ito S， Mochizuki Y， et al.Long-term follow up of patients who were positive for peritoneal lavage cytology： final report from the CCOG0301 study［J］.Gastric Cancer， 2012， 15（3）：335-337.
［35］	Kano K， Aoyama T， Maezawa Y， et al.The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy［J］.Int J Clin Oncol， 2017， 22（5）： 887-896.
［36］	Rha SY， Oh DY， Ya-ez P， et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer （KEYNOTE-859）： A multicentre， randomised，double-blind， phase 3 trial［J］.Lancet Oncol， 2023， 24（11）： 1181-1195.
［37］	Janjigian YY， Ajani JA， Moehler M， et al.First-line nivolumab plus chemotherapy for advanced gastric， gastroesophageal junction，and esophageal adenocarcinoma： 3-year follow-up of the phase checkmate 649 trial［J］.J Clin Oncol， 2024， 42（17）： 2012-2020.
［38］	Xu J， Jiang H， Pan Y， et al.Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer： the ORIENT-16 randomized clinical trial［J］.JAMA， 2023， 330（21）：2064-2074.
［39］	Qiu MZ， Oh DY， Kato K， et al.Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma：RATIONALE-305 randomised， double blind， phase 3 trial［J］.BMJ，2024， 385： e078876.
［40］	Janjigian YY， Kawazoe A， Bai Y， et al.Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma： interim analyses from the phase 3 KEYNOTE-811 randomised placebo- controlled trial［J］.Lancet， 2023， 402（10418）： 2197-2208.
［41］	Sun YQ， Zhong Q， Lv CB， et al.The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer： A multicentre real-world clinical study［J］.Int J Surg， 2024， 110（8）： 4830-4838.
［42］	Chen Z， Chen Y， Sun Y， et al.Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data［J］.Signal Transduct Target Ther， 2024， 9（1）：222.
［43］	Fuchs CS， Doi T， Jang RW， et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer： phase 2 clinical KEYNOTE-059 trial［J］.JAMA Oncol， 2018， 4（5）： e180013.
［44］	Fuchs CS， Özgüroğlu M， Bang YJ， et al.Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer： 2-year update of the randomized phase 3 KEYNOTE-061 trial［J］.Gastric Cancer， 2022，25（1）： 197-206.
［45］	Shitara K， Van Cutsem E， Bang YJ， et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line， advanced gastric cancer： the KEYNOTE-062 phase 3 randomized clinical trial［J］.JAMA Oncol， 2020， 6（10）： 1571-1580.
［46］	Kawakami H， Hironaka S， Esaki T， et al.An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as firstline therapy for microsatellite instabilityhigh advanced gastric or esophagogastric junction cancer （NO LIMIT， WJOG13320G/CA209-7W7）［J］.Cancers （Basel）， 2021， 13（4）： 805.
［47］	André T， Tougeron D， Piessen G， et al.Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma： the GERCOR NEONIPIGA phase study［J］.J Clin Oncol， 2023， 41（2）： 255-265.
［48］	Chen GM， Yuan SQ， Nie RC， et al.Surgical outcome and longterm survival of conversion surgery for advanced gastric cancer［J］.Ann Surg Oncol， 2020， 27（11）： 4250-4260.
［49］	中华医学会外科学分会腹腔镜与内镜外科学组，中国研究型医院学会机器人与腹腔镜外科专业委员会，中国抗癌协会腔镜与机器人外科分会，等.腹腔镜胃癌手术操作指南（2023 版）［J］.中华消化外科杂志， 2023， 22（4）： 425-436.
［50］	Min SH， Won Y， Lee K， et al.Laparoscopic gastrectomy and metastasectomy for stage Ⅳ gastric cancer［J］.Surg Endosc， 2021，35（4）： 1879-1887.
［51］	Yu P， Hu C， Wang Y， et al.Preoperative chemotherapy combined with para-aortic lymph node dissection has clinical value in the treatment of gastric cancer with para-aortic lymph node metastases［J］.BMC Surg， 2022， 22（1）： 401.
［52］	中国抗癌协会胃癌专业委员会，中国医师协会外科医师分会上消化道外科医师专家工作组，中国老年保健协会消化系统疾病诊疗分会，等.胃癌肝转移诊断与综合治疗中国专家共识（2024 版）［J］.中国实用外科杂志， 2024， 44（5）： 481-489.
［53］	Al-Batran SE， Homann N， Pauligk C， et al.Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer：the AIO-FLOT3 trial［J］.JAMA Oncol， 2017， 3（9）： 1237-1244.
［54］	Al-Batran SE， Goetze TO， Mueller DW， et al.The RENAISSANCE（AIO-FLOT5） trial： effect of chemotherapy alone vs.chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction-a phase Ⅲ trial of the German AIO/CAO-V/CAOGI［J］.BMC Cancer， 2017， 17（1）： 893.
［55］	Lee JW， Choi MH， Lee YJ， et al.Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection［J］.BMC Cancer， 2017， 17（1）： 185.
［56］	Guner A， Son T， Cho I， et al.Liver-directed treatments for liver metastasis from gastric adenocarcinoma： comparison between liver resection and radiofrequency ablation［J］.Gastric Cancer， 2016，19（3）： 951-960.
［57］	Iijima Y， Akiyama H， Atari M， et al.Pulmonary resection for metastatic gastric cancer［J］.Ann Thorac Cardiovasc Surg， 2016，22（4）： 230-236.
［58］	Shigenobu T， Ohtsuka T， Hanawa R， et al.Prognostic impact of visceral pleural invasion in resected solitary lung metastases from gastric cancer［J］.Ann Thorac Cardiovasc Surg， 2023， 29（6）： 279-286.
［59］	Kamimura G， Aoki M， Umehara T， et al.Prognostic outcomeof pulmonary resection for pulmonary metastases from gastric cancer［J］.Ann Thorac Cardiovasc Surg， 2024， 30（1）： 24-00044.
［60］	Osoegawa A， Kometani T， Fukuyama S， et al.Prognostic factors for survival after resection of pulmonary metastases from colorectal carcinoma［J］.Ann Thorac Cardiovasc Surg， 2016， 22（1）： 6-11.
［61］	Aurello P， Petrucciani N， Giulitti D， et al.Pulmonary metastases from gastric cancer： is there any indication for lung metastasectomy？A systematic review［J］.Med Oncol， 2016， 33（1）： 9.
［62］	程向东，季加孚.胃癌卵巢转移诊断和治疗中国专家共识（2021 版）［J］.中国肿瘤， 2022， 31（2）： 81-87.
［63］	Ma F， Li Y， Li W， et al.Metastasectomy improves the survival of gastric cancer patients with krukenberg tumors： A retrospective analysis of 182 patients［J］.Cancer Manag Res， 2019， 11： 10573-10580.
［64］	Yonemura Y， Elnemr A， Endou Y， et al.Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer［J］.World J Gastrointest Oncol， 2010， 2（2）： 85-97.
［65］	Aizawa M， Nashimoto A， Yabusaki H， et al.The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy［J］.Surg Today， 2015， 45（5）： 611-617.

[1]	Sizhuo Wang, Xiaoxin Duan, Long Chen, Shengli Dong. Causal effect of gut microbiome， blood metabolites and gastric cancer： A mediated Mendelian randomization study in East Asian populations [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 163-168.
[2]	Long Chen, Xiaoxin Duan, Sizhuo Wang, Shengli Dong. Current status of immunotherapy for gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 177-182.
[3]	Shigong Chen, Wenjing Wang, Xiulan Li, Bo Long, Zuoyi Jiao. Application and research progress of arginine and glutamine in gastric cancer treatment [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 183-187.
[4]	Yilin Qiu, Kun He. Progress in the treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 197-202.
[5]	Haoyu Wang, Shuanyuan Yang, Yanshun Ren, Zhiqiang Yin. Clinical comparative study of two modified esophagojejunostomies in laparoscopic total gastrectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 425-428.
[6]	Weijun Yang, Wenwen Zhang, Kai Fu. Efficacy observation of laparoscopic radical gastrectomy with single incision in the treatment of early and middle-stage gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 434-437.
[7]	Huazhi Li, Haitao Sun, Guang Cao, Yajing Zhang. Application of complete mesocolic excision based on membrane anatomy + D2 radical resection in the treatment of advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 262-265.
[8]	Zhixiang Wang, Zhanyang He. Clinical study of different lymph node dissections in locally advanced gastric cancer with limited metastasis of lymph node No.16 [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 266-269.
[9]	Yuqing Li, Gang Wang, Qiang Li, Yunchuan Li, Mingxin Du. Influence of different anastomosis techniques on patients undergoing laparoscopic radical distal gastrectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 286-289.
[10]	Haixia He, Shoumin Bai. The utilization of radiotherapy in bladder-sparing treatment for muscle-invasive bladder cancer and the refinement of strategies to minimize toxicity [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 288-295.
[11]	Hong Zeng. Interpretation of commonly used immunohistochemical markers in pathological reports of bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 296-302.
[12]	Minimally Invasive Surgery Professional Committee of the Chinese Research Hospital Association The, Intelligent Medicine Professional Committee of the Chinese Research Hospital Association The. Expert consensus on pancreatic duct (repair) surgery [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2025, 18(02): 65-72.
[13]	Minimally Invasive Surgery Professional Committee of the Chinese Research Hospital Association The, Intelligent Medicine Professional Committee of the Chinese Research Hospital Association The. Expert consensus on robotic radical resection for perihilar cholangiocarcinoma [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2025, 18(02): 73-77.
[14]	Hongbin Zhang, Zhenyu Yang, Kai Tan, Guan Liu, Lei Shang, Xilin Du. Influencing factors and prediction model for surgery in patients with unresectable hepatocellular carcinoma after conversion treatments [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(03): 387-394.
[15]	. Recent advances in surgical strategies for hepatic alveolar echinococcosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(03): 475-480.

Please choose a citation manager

Content to export